CN115768487A - 用于面肩肱型肌营养不良症的crispr抑制 - Google Patents

用于面肩肱型肌营养不良症的crispr抑制 Download PDF

Info

Publication number
CN115768487A
CN115768487A CN202180041592.XA CN202180041592A CN115768487A CN 115768487 A CN115768487 A CN 115768487A CN 202180041592 A CN202180041592 A CN 202180041592A CN 115768487 A CN115768487 A CN 115768487A
Authority
CN
China
Prior art keywords
lys
leu
glu
ile
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041592.XA
Other languages
English (en)
Chinese (zh)
Inventor
P·L·琼斯
C·L·希梅达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nevada Research and Innovation Corp
Original Assignee
Nevada Research and Innovation Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nevada Research and Innovation Corp filed Critical Nevada Research and Innovation Corp
Publication of CN115768487A publication Critical patent/CN115768487A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180041592.XA 2020-04-17 2021-04-06 用于面肩肱型肌营养不良症的crispr抑制 Pending CN115768487A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011476P 2020-04-17 2020-04-17
US63/011,476 2020-04-17
PCT/US2021/025940 WO2021211325A1 (en) 2020-04-17 2021-04-06 Crispr-inhibition for facioscapulohumeral muscular dystrophy

Publications (1)

Publication Number Publication Date
CN115768487A true CN115768487A (zh) 2023-03-07

Family

ID=78084611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041592.XA Pending CN115768487A (zh) 2020-04-17 2021-04-06 用于面肩肱型肌营养不良症的crispr抑制

Country Status (11)

Country Link
US (1) US20230174958A1 (https=)
EP (1) EP4135778A4 (https=)
JP (1) JP2023522020A (https=)
KR (1) KR20230003511A (https=)
CN (1) CN115768487A (https=)
AU (1) AU2021257213A1 (https=)
BR (1) BR112022020945A2 (https=)
CA (1) CA3175625A1 (https=)
IL (1) IL297113A (https=)
MX (1) MX2022012965A (https=)
WO (1) WO2021211325A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117448380A (zh) * 2023-12-22 2024-01-26 上海元戊医学技术有限公司 iPSC来源的COL10A1蛋白低表达MSC细胞株的构建方法及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230023612A (ko) 2020-04-02 2023-02-17 마이레큘, 인크. 조작된 올리고뉴클레오티드를 사용한 표적화된 억제
WO2022045366A1 (en) * 2020-08-31 2022-03-03 Modalis Therapeutics Corporation Method for treating facioscapulohumeral muscular dystrophy (fshd) by targeting dux4 gene
WO2024020444A2 (en) * 2022-07-20 2024-01-25 Nevada Research & Innovation Corporation Muscle-specific regulatory cassettes
WO2025019820A1 (en) * 2023-07-19 2025-01-23 Nevada Research & Innovation Corporation All in one vectors for the treatment of facioscapulohumeral muscular dystrophy
WO2026039783A1 (en) * 2024-08-16 2026-02-19 Sarepta Therapeutics, Inc. Deficient cas-transcriptional repressor fusions for regulation of gene expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061510A (zh) * 2013-12-12 2016-10-26 布罗德研究所有限公司 用于基因组编辑的crispr‑cas系统和组合物的递送、用途和治疗应用
WO2018057863A1 (en) * 2016-09-23 2018-03-29 University Of Massachusetts Silencing of dux4 by recombinant gene editing complexes
WO2018085842A1 (en) * 2016-11-07 2018-05-11 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
WO2019051290A1 (en) * 2017-09-07 2019-03-14 The Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR THE TREATMENT OF FACIO-SCAPULO-HUMERAL DYSTROPHY
CN111868237A (zh) * 2017-10-05 2020-10-30 弗尔康医疗公司 P38抑制剂降低dux4表达的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192880B1 (en) * 2010-08-18 2019-10-09 Fred Hutchinson Cancer Research Center Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
PL3097197T3 (pl) * 2014-01-21 2021-06-28 Vrije Universiteit Brussel Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061510A (zh) * 2013-12-12 2016-10-26 布罗德研究所有限公司 用于基因组编辑的crispr‑cas系统和组合物的递送、用途和治疗应用
WO2018057863A1 (en) * 2016-09-23 2018-03-29 University Of Massachusetts Silencing of dux4 by recombinant gene editing complexes
WO2018085842A1 (en) * 2016-11-07 2018-05-11 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
WO2019051290A1 (en) * 2017-09-07 2019-03-14 The Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR THE TREATMENT OF FACIO-SCAPULO-HUMERAL DYSTROPHY
CN111868237A (zh) * 2017-10-05 2020-10-30 弗尔康医疗公司 P38抑制剂降低dux4表达的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHARIS L HIMEDA等: "Identification of epigenetic regulators of DUX4-fl for targeted therapy of facioscapulohumeral muscular dystrophy", MOL THER, 26 April 2008 (2008-04-26) *
曾淑俊: "SFPQ蛋白对骨骼肌成肌细胞分化及融合的影响", 万方学位论文, 8 September 2021 (2021-09-08) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117448380A (zh) * 2023-12-22 2024-01-26 上海元戊医学技术有限公司 iPSC来源的COL10A1蛋白低表达MSC细胞株的构建方法及其应用

Also Published As

Publication number Publication date
JP2023522020A (ja) 2023-05-26
EP4135778A4 (en) 2024-05-29
IL297113A (en) 2022-12-01
US20230174958A1 (en) 2023-06-08
AU2021257213A1 (en) 2022-11-03
MX2022012965A (es) 2023-01-18
CA3175625A1 (en) 2021-10-21
EP4135778A1 (en) 2023-02-22
BR112022020945A2 (pt) 2022-12-27
KR20230003511A (ko) 2023-01-06
WO2021211325A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7720623B2 (ja) 遺伝子操作されたａｄａｒのリクルートを介したｒｎａ及びｄｎａ塩基の編集
CN115768487A (zh) 用于面肩肱型肌营养不良症的crispr抑制
JP7631215B2 (ja) Ｔｔｒガイドｒｎａと、ｒｎａガイドｄｎａ結合剤をコードするポリヌクレオチドとを含む組成物および方法
JP2025066771A (ja) サプレッサーｔＲＮＡ及びデアミナーゼによる変異のＲＮＡターゲティング
US20230061936A1 (en) Methods of dosing circular polyribonucleotides
TW202033224A (zh) 藉靶向肌營養相關蛋白基因治療肌肉萎縮症之方法
US11439692B2 (en) Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
JP2020527030A (ja) 肝臓において目的のタンパク質を発現するためのプラットフォーム
EP4289954A1 (en) Sgrna targeting aqp1 mrna, and vector and use thereof
CN117580941A (zh) 多重CRISPR/Cas9介导的靶基因激活系统
EP4491720A1 (en) Compositions and methods for increasing deletion efficiency of nucleic acid segment by modulation of nhej repair pathway
TW202112797A (zh) 經由靶向lama1基因治療肌肉萎縮症的方法
KR20240040112A (ko) 방법
EP4048796B1 (en) Compositions and methods comprising viral vector systems for multiplexed activation of endogenous genes as immunotherapy and viral-based immune-gene therapy
TW202246510A (zh) 以crispr/slucas9治療第1型肌強直性營養不良之組合物及方法
EP2739738B1 (en) Use of integrase for targeted gene expression
JP2023518051A (ja) 改良されたガイドｒｎａを含む組成物及び方法
WO2025201481A1 (en) Crispr-cas systems
WO2025019820A1 (en) All in one vectors for the treatment of facioscapulohumeral muscular dystrophy
WO2024238909A1 (en) Programmable rna scaffolds for multivariate effector recruitment using crispr/cas
Economos Peptide Nucleic Acids and CRISPR-Cas9: Mechanisms and Rational Applications for Gene Editing Systems
WO2025184186A1 (en) Excision of exon 53 for treatment of duchenne muscular dystrophy
TW202302848A (zh) 以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法
IL322419A (en) Genome editing agents and methods for treating cystic fibrosis
HK40101152A (zh) 强直性肌肉营养不良1型治疗药

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination